Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Cash & Equivalents: 2017-2025

Historic Revenue - Interest and Investment Income for Autolus Therapeutics (AUTL) over the last 4 years, with Sep 2023 value amounting to $406.1 million.

  • Autolus Therapeutics' Cash & Equivalents fell 86.89% to $86.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $86.1 million, marking a year-over-year decrease of 86.89%. This contributed to the annual value of $227.4 million for FY2024, which is 5.09% down from last year.
  • Autolus Therapeutics' Cash & Equivalents amounted to $86.1 million in Q3 2025, which was down 30.45% from $123.8 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Cash & Equivalents ranged from a high of $758.5 million in Q1 2024 and a low of $86.1 million during Q3 2025.
  • In the last 3 years, Autolus Therapeutics' Cash & Equivalents had a median value of $273.5 million in 2023 and averaged $354.5 million.
  • Its Revenue - Interest and Investment Income has fluctuated over the past 5 years, first decreased by 11.06% in 2022, then soared by 53.92% in 2023.
  • Autolus Therapeutics' Revenue - Interest and Investment Income (Quarterly) stood at $314.6 million in 2019, then grew by 0.77% to $317.1 million in 2020, then fell by 6.45% to $405.6 million in 2021, then rose by 20.89% to $490.3 million in 2022, then skyrocketed by 53.92% to $406.1 million in 2023.
  • Its Cash & Equivalents stands at $86.1 million for Q3 2025, versus $123.8 million for Q2 2025 and $95.8 million for Q1 2025.